Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.
AffiliationDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Box 403, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. firstname.lastname@example.org
MetadataShow full item record
AbstractWorldwide, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality and, until screening detects early disease, treatment for the majority of patients will consist of radiation therapy, chemotherapy or combinations thereof. Modern mono and doublet chemotherapy regimens have translated into modest increases in life expectancy and improved quality of life, but at the expense of systemic and pulmonary adverse events (AEs). There is a great unmet need to provide effective therapy for advanced NSCLC that does not have the toxicity burden of conventional chemotherapy and radiotherapy. Novel drugs that inhibit a range of growth factor receptors, such as the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib ('Iressa') and erlotinib ('Tarceva') or the monoclonal antibody cetuximab ('Erbitux'), have recently been evaluated. Having demonstrated antitumour activity and rapid symptom improvement in pretreated patients with advanced NSCLC, gefitinib was approved in the USA, Japan and other countries. Gefitinib is well tolerated with a low incidence of grade 3/4 AEs. Interstitial lung disease has been reported in a small number of patients receiving gefitinib, although this may be attributed to other treatments and conditions. Nevertheless, although the use of novel treatments requires vigilance for unexpected AEs such as pulmonary toxicity, in this area of high unmet clinical need, the benefits outweigh the risks in patients for whom no other proven effective treatment exists.
CitationTreatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. 2004, 91 Suppl 2:S11-7 Br. J. Cancer
JournalBritish Journal of Cancer
- Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
- Authors: Blackledge G, Averbuch S
- Issue date: 2004 Feb 9
- Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
- Authors: Von Pawel J
- Issue date: 2004 May 1
- Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
- Authors: Langer CJ
- Issue date: 2004 Mar 1
- Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
- Authors: Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ
- Issue date: 2004 Aug 19
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
- Authors: Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH
- Issue date: 2004 Mar 1